Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Zhejiang Hisun Pharmaceutical Co Ltd (Hisun) is a pharmaceutical company that develops, manufactures, and distributes drug substances and preparations. The company offers products such as active pharmaceutical ingredients in various therapeutic areas including oncology, cardiovascular, anti-infectives, other drugs, animal healthcare and antibody-drug conjugate (ADC) small molecules. It provides its products in the forms of tablets, injections, capsules, granules, drops, syrups and other solid formulations. The company distributes its products in domestic markets and overseas markets. Hisun is headquartered in Taizhou, Zhejiang, China.
Headquarters
China
Address
No. 48, Waisha Road, Jiaojiang District, Taizhou, Zhejiang, 318000
Website
www.hisunpharm.com
Telephone
86 576 88827890
No of Employees
8,751
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
600267 (SHA)
Revenue (2024)
$1.5B
2%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
-10.1%
(2024 vs 2023)
Market Cap*
$1.8B
Net Profit Margin (2024)
XYZ
-11.7%
(2024 vs 2023)
* As of and is in US$
Zhejiang Hisun Pharmaceutical Co Ltd premium industry data and analytics
Products and Services
| Products |
|---|
| Active Pharmaceutical Ingredients: |
| Oncology Products |
| Cardiovascular Products |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Zhejiang Hisun Pharmaceutical Co Ltd | Shanghai Fosun Pharmaceutical (Group) Co Ltd | Jiangsu Hengrui Pharmaceuticals Co Ltd | Tasly Pharmaceutical Group Co Ltd | Kangmei Pharmaceutical Co Ltd |
|---|---|---|---|---|---|
| Headquarters | China | China | China | China | China |
| City | Taizhou | Shanghai | Lianyungang | Tianjin | Shenzhen |
| State/Province | Zhejiang | Shanghai | Jiangsu | Tianjin | Guangdong |
| No. of Employees | 8,751 | 40,603 | 20,602 | 10,563 | 5,492 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Xiao Weihong | President; Chairman | Executive Board | 2024 | 58 |
| Du Jiaqiu | Director; Senior Vice President | Executive Board | 2022 | 52 |
| Jiang Ling | Chief Financial Officer; Senior Vice President | Senior Management | 2024 | 55 |
| Jiwei | Director - Employee | Senior Management | 2025 | 39 |
| Yang Zhiqing | Senior Vice President | Senior Management | 2019 | 51 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer